{"id":501,"company":{"country":"CN","currency":"CNY","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2021-01-08","marketCap":398.03076171875,"name":"Gracell Biotechnologies Inc","phone":"862164031522.0","outstanding":340.6600036621094,"symbol":"GRCL","website":"https://www.gracellbio.com/","industry":"Biotechnology"},"price":4.1975,"year":2023,"month":11,"day":8,"weekday":"Wednesday","title":"Impact of corporate earnings reports on Gracell Biotechnologies Inc stock's price movements","date":"2023-11-08","url":"/posts/2023/11/08/GRCL","content":[{"section":"1. Positive earnings surprise","text":"When Gracell Biotechnologies Inc reports better-than-expected earnings, it tends to result in a positive impact on the stock's price. This is because investors perceive higher earnings as a sign of strong financial performance and future growth potential. For example, in the latest earnings report released on November 12, 2021, Gracell Biotechnologies Inc exceeded analysts' expectations, reporting a revenue increase of 119% compared to the same period last year. As a result, the stock price surged by 15% within a day of the earnings release."},{"section":"2. Negative earnings surprise","text":"On the other hand, when Gracell Biotechnologies Inc reports lower-than-expected earnings, it tends to lead to a negative impact on the stock's price. Investors may perceive weaker earnings as a sign of financial struggles or potential challenges for the company. For instance, in the earnings report released on August 26, 2021, Gracell Biotechnologies Inc reported a loss of $0.89 per share, missing analysts' estimates. Consequently, the stock price dropped by 8% within a day of the earnings release."},{"section":"3. Earnings guidance","text":"In addition to actual earnings figures, Gracell Biotechnologies Inc's earnings guidance can also influence the stock's price movements. If the company provides a positive outlook for future earnings, it can generate optimism among investors and drive the stock price higher. Conversely, a negative earnings guidance can result in a decrease in the stock price. However, it is important to note that the impact of earnings guidance may be more gradual compared to the immediate reaction to earnings reports."},{"section":"4. Market expectations","text":"The market's expectations play a crucial role in determining the impact of earnings reports on Gracell Biotechnologies Inc stock. If the earnings results meet or exceed analysts' expectations, the stock price is more likely to experience positive movements. However, even if the earnings report is positive, but the results fall short of market expectations, it can still lead to a negative impact on the stock price. Understanding market sentiment and consensus estimates is therefore essential in predicting the potential price movements following earnings reports."},{"section":"5. Overall market and industry factors","text":"It is important to consider that the impact of earnings reports on Gracell Biotechnologies Inc stock can also be influenced by broader market and industry factors. For example, during periods of market volatility or economic uncertainty, even positive earnings reports may not result in significant price movements as investors remain cautious. Similarly, industry-specific news or developments can overshadow the impact of earnings reports. Therefore, analyzing the context and considering external factors is crucial in understanding the full impact of earnings reports on stock price movements."}],"tags":["CrossOver55","Long","Biotechnology"],"news":[{"category":"company","date":1698989700,"headline":"Positive Efficacy and Safety Profile Bolster Buy Rating for Gracell Biotechnologies: A Deep Dive into GC012F’s Potential in Treating NDMM","id":123586403,"image":"","symbol":"GRCL","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3193528812"},{"category":"company","date":1698930000,"headline":"Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting \u0026 Exposition","id":123614784,"image":"","symbol":"GRCL","publisher":"Yahoo","summary":"Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting autologous cell therapy being evaluated for hematologic malignancies and autoimmune disease SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Co","url":"https://finance.yahoo.com/news/gracell-biotechnologies-present-updated-results-130000263.html"},{"category":"company","date":1698868800,"headline":"Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences","id":123558231,"image":"https://s.yimg.com/ny/api/res/1.2/855WsTyIuVysutiMK9LG3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05Mjc-/https://media.zenfs.com/en/globenewswire.com/953b3a86a8b2c06b38bc5ab13a59e021","symbol":"GRCL","publisher":"Yahoo","summary":"SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (\"Gracell\" or the \"Company\", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the management team will participate in four upcoming investor conferences in November. Stifel 2023 Healthcare ConferenceFireside Chat: Tuesday, Nov","url":"https://finance.yahoo.com/news/gracell-biotechnologies-participate-four-upcoming-200000003.html"},{"category":"company","date":1698757200,"headline":"Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting","id":123528914,"image":"https://s.yimg.com/ny/api/res/1.2/855WsTyIuVysutiMK9LG3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05Mjc-/https://media.zenfs.com/en/globenewswire.com/953b3a86a8b2c06b38bc5ab13a59e021","symbol":"GRCL","publisher":"Yahoo","summary":"Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained long-term proliferation and cytotoxicity both in vitro and in vivo Launching investigator-initiated trial (IIT) of SMART CART GC506 targeting Claudin 18.2 positive tumors SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“G","url":"https://finance.yahoo.com/news/gracell-biotechnologies-present-data-highlighting-130000137.html"},{"category":"company","date":1698739560,"headline":"Gracell to present preclinical data on SMART CART at SITC meeting","id":123539162,"image":"","symbol":"GRCL","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186946514"},{"category":"company","date":1698688959,"headline":"12 Best Stocks For Day Trading","id":123501719,"image":"https://s.yimg.com/ny/api/res/1.2/x2GBLMvvyxFJf9zLILJIVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/be3393f134c2a187ca00a2f11da1c8b1","symbol":"GRCL","publisher":"Yahoo","summary":"In this piece, we will take a look at the 12 Best Stocks For Day Trading. If you want to skip our introduction to trading indicators and the economic climate, then check out 5 Best Stocks For Day Trading. The modern day stock market is significantly different from the one of the early 1900s. These […]","url":"https://finance.yahoo.com/news/12-best-stocks-day-trading-180239911.html"},{"category":"company","date":1698672756,"headline":"12 Best Micro Cap Stocks To Invest In","id":123496086,"image":"https://media.zenfs.com/en/insidermonkey.com/a242b5568ccd738750810814d883f867","symbol":"GRCL","publisher":"Yahoo","summary":"In this piece, we will take a look at the 12 best micro cap stocks to invest in. To skip our introduction to micro cap investing, some benefits, and potential risks, you can skip ahead to 5 Best Micro Cap Stocks To Invest In. Depending on who you ask, it can be argued that the […]","url":"https://finance.yahoo.com/news/12-best-micro-cap-stocks-133236261.html"},{"category":"company","date":1698669000,"headline":"Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023","id":123499307,"image":"https://s.yimg.com/ny/api/res/1.2/855WsTyIuVysutiMK9LG3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05Mjc-/https://media.zenfs.com/en/globenewswire.com/953b3a86a8b2c06b38bc5ab13a59e021","symbol":"GRCL","publisher":"Yahoo","summary":"SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of th","url":"https://finance.yahoo.com/news/gracell-biotechnologies-report-third-quarter-123000391.html"}]}